Cell No. : Cell Name
RCB1169 : TGBC18TKB
update : 2021/02/26
|
| Comment | Papillotubular adenocarcinoma of the Vater's papilla. Application consideration |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Ohno, T. & Todoroki, T.
|
| Originator |
Kim, B. & Ohno, T.
|
| Year of deposit |
1995
|
| Another name |
UcFu
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Female
|
| Age at sampling |
79 years
|
| Tissue |
duodenum
|
| Disease name |
papillotublar adenocarcinoma
|
| Classification |
cancer
|
| Year of origin |
1995
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Medium and additives |
|
DMEM (low glucose) + 5% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% trypsin
|
Culture information
|
Passage ratio |
|
1 : 4 split
|
| SC frequency |
|
Subculture : once/1-2 weeks, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| STR(human) |
|
OK
|
| Virus (HIV) |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
57-63(50) : 57(3),58(39,59(7),60(19),61(10),62(5)/
|
| Reference information |
Reference |
1
|
| User's Publication |
5
|
| User's Publication |
|
13465
Wang CY, Chao YJ, Chen YL, Wang TW, Phan NN, Hsu HP, Shan YS, Lai MD.
Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer
Int J Med Sci
2021
18(1):256-269
PubMed ID: 33390794
|
|
13152
Cheng LC, Chao YJ, Wang CY, Phan NN, Chen YL, Wang TW, Hsu HP, Lin YJ, Shan YS, Lai MD.
Cancer-Derived Transforming Growth Factor-β Modulates Tumor-Associated Macrophages in Ampullary Cancer.
Onco Targets Ther
2020
PubMed ID: 32821120
|
|
3738
Yamashita-Kashima Y, Yoshimura Y, Fujimura T, Shu S, Yanagisawa M, Yorozu K, Furugaki K, Higuchi R, Shoda J, Harada N.
Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
Cancer Chemother Pharmacol.
2019
83(4):659-671
PubMed ID: 30659304
|
|
3727
Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM
K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
Mol Oncol
2017
11(9):1130-1142
PubMed ID: 28544747
|
|
3713
Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K, Adachi Y, Endo T, Imai K, Shinomura Y.
Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers.
Oncogene
2005
24(53):7946-52
PubMed ID: 16007117
|
Back
Top
CELL BANK Website